1. AB0759 FOUR-YEAR EFFICACY AND SAFETY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: A POOLED ANALYSIS FROM VOYAGE 1 AND VOYAGE 2. (2nd June 2020) Authors: Reich, K.; Dutz, J.; Foley, P.; Thaçi, D.; Vender, R.; Song, M.; Miller, M.; You, Y.; Li, S.; Shen, Y. K.; Armstrong, A. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1677 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. (18th July 2018) Authors: Gordon, K.B.; Armstrong, A.W.; Han, C.; Foley, P.; Song, M.; Wasfi, Y.; You, Y.; Shen, Y.‐K.; Reich, K. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 11(2018) Page Start: 1940 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. (10th October 2016) Authors: Thaçi, D.; Kimball, A.; Foley, P.; Poulin, Y.; Levi, E.; Chen, R.; Feldman, S.R. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 3(2017) Page Start: 498 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. (1st December 2017) Authors: Cohen, A.D.; Wu, J.J.; Puig, L.; Chimenti, S.; Vender, R.; Rajagopalan, M.; Romiti, R.; de la Cruz, C.; Skov, L.; Zachariae, C.; Young, H.S.; Foley, P.; van der Walt, J.M.; Naldi, L.; Prens, E.P.; Blauvelt, A. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. (27th November 2017) Authors: Cohen, A.D.; Wu, J.J.; Puig, L.; Chimenti, S.; Vender, R.; Rajagopalan, M.; Romiti, R.; de la Cruz, C.; Skov, L.; Zachariae, C.; Young, H.S.; Foley, P.; van der Walt, J.M.; Naldi, L.; Prens, E.P.; Blauvelt, A. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. (27th November 2017) Authors: Cohen, A.D.; Wu, J.J.; Puig, L.; Chimenti, S.; Vender, R.; Rajagopalan, M.; Romiti, R.; de la Cruz, C.; Skov, L.; Zachariae, C.; Young, H.S.; Foley, P.; van der Walt, J.M.; Naldi, L.; Prens, E.P.; Blauvelt, A. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis. (1st December 2017) Authors: Papp, K.; Bachelez, H.; Costanzo, A.; Foley, P.; Gooderham, M.; Kaur, P.; Philipp, S.; Spelman, L.; Zhang, N.; Strober, B. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis4. (1st December 2017) Authors: Papp, K.; Bachelez, H.; Costanzo, A.; Foley, P.; Gooderham, M.; Kaur, P.; Philipp, S.; Spelman, L.; Zhang, N.; Strober, B. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. (20th October 2014) Authors: Rubel, D.M.; Spelman, L.; Murrell, D.F.; See, J.‐A.; Hewitt, D.; Foley, P.; Bosc, C.; Kerob, D.; Kerrouche, N.; Wulf, H.C.; Shumack, S. Journal: British journal of dermatology Issue: Volume 171:Number 5(2014:Nov.) Page Start: 1164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. (20th October 2014) Authors: Rubel, D.M.; Spelman, L.; Murrell, D.F.; See, J.‐A.; Hewitt, D.; Foley, P.; Bosc, C.; Kerob, D.; Kerrouche, N.; Wulf, H.C.; Shumack, S. Journal: British journal of dermatology Issue: Volume 171:Number 5(2014:Nov.) Page Start: 1164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗